REAL-LIFE DATA IN RHEUMATOID ARTHRITIS PATIENTS USING BARICITINIB AT A SINGLE CENTER-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

REAL-LIFE DATA IN RHEUMATOID ARTHRITIS PATIENTS USING BARICITINIB AT A SINGLE CENTER

Published:2024-03-01 Issue:1 Volume:2 Page:15-18
ISSN:2980-1559
Container-title:Rheumatology Quarterly
language:
Short-container-title:qrheumatol

Author:

Ergün Betül^ORCID,Küçük Adem^ORCID

Publisher

Galenos Yayinevi

Reference9 articles.

1. A JAK Inhibitor for treatment of rheumatoid arthritis: the baricitinib experience;Taylor;J Clin Med,2023

2. Efficacy and safety of baricitinib in Chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE;Yang;Rheumatol Ther,2020

3. Correction to: Real-world treatment patterns and clinical outcomes of baricitinib in rheumatoid arthritis patients in Spain: results of a multicenter, observational study in routine clinical practice (the ORBIT-RA study);Hernández-Cruz;Rheumatol Ther,2022

4. Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry;Takahashi;Sci Rep,2020

5. Safety and Effectiveness of Baricitinib in Chinese patients with moderate-to-severe rheumatoid arthritis: 24-week results from a post-marketing safety study;CY;Rheumatol Ther,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3